Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis
This study is currently recruiting patients.
Sponsored by: | FDA Office of Orphan Products Development University of North Carolina
|
---|---|
Information provided by: | FDA Office of Orphan Products Development |
Purpose
OBJECTIVES: I. Determine the bioavailability and biologic effect of alendronate on bone metabolism in patients with cystic fibrosis. II. Assess the safety and efficacy of this treatment regimen in improving osteoporosis in this patient population.
Condition | Treatment or Intervention |
---|---|
Osteoporosis Cystic Fibrosis |
Drug: alendronate sodium Drug: calcium carbonate Drug: cholecalciferol |
MedlinePlus related topics: Cystic Fibrosis; Osteoporosis
Genetics Home Reference related topics: cystic fibrosis
Study Type: Interventional
Study Design: Treatment, Safety/Efficacy Study
Expected Total Enrollment: 60
Study start: October 1998
PROTOCOL OUTLINE: This is a randomized, double blind study. Patients will be stratified according to sex (male vs female) and osteoporosis disease severity (mild vs severe). Patients are randomized to one of two treatment arms. Patients undergo bioavailability assessment to confirm the ability to absorb alendronate. Arm I: Patients receive calcium and vitamin D supplements with a placebo daily for one month. Arm II: Patients receive calcium and vitamin D supplements with oral alendronate daily for one month. Treatment continues if differences are seen in bone mineral density between the treatment arms. Patients are followed for biochemical response at week 6, 12, and 52. Bone mineral density is measured at 1 year and 2 years.
Eligibility
Ages Eligible for Study: 18 Years - 45 Years, Genders Eligible for Study: Both
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |